Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia.

CONCLUSION: Our case report supports the potential use of anti-IL-5 therapy for remission of patients with CEP with recurrent relapses. Whether, it would also be an effective initial therapy might also be an area that deserves future investigation. PMID: 30444149 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research